S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
Log in

NASDAQ:AERIAerie Pharmaceuticals Stock Price, Forecast & News

$12.70
+0.32 (+2.58 %)
(As of 08/14/2020 01:24 PM ET)
Add
Compare
Today's Range
$12.27
Now: $12.70
$12.86
50-Day Range
$11.56
MA: $13.21
$15.79
52-Week Range
$10.80
Now: $12.70
$26.26
Volume10,301 shs
Average Volume918,983 shs
Market Capitalization$590.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More
Aerie Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$1.93 per share

Profitability

Net Income$-199,580,000.00
Net Margins-247.36%

Miscellaneous

Employees353
Market Cap$590.73 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$12.70
+0.32 (+2.58 %)
(As of 08/14/2020 01:24 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock price been impacted by Coronavirus?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AERI stock has decreased by 12.7% and is now trading at $12.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals
.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced its earnings results on Thursday, August, 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.79) by $0.04. Aerie Pharmaceuticals had a negative return on equity of 107.42% and a negative net margin of 247.36%.
View Aerie Pharmaceuticals' earnings history
.

What price target have analysts set for AERI?

13 analysts have issued 1 year price targets for Aerie Pharmaceuticals' shares. Their forecasts range from $17.00 to $50.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $30.08 in the next twelve months. This suggests a possible upside of 136.9% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
.

Has Aerie Pharmaceuticals been receiving favorable news coverage?

News headlines about AERI stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Aerie Pharmaceuticals
.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 8,050,000 shares, a drop of 10.6% from the July 15th total of 9,000,000 shares. Based on an average daily trading volume, of 879,200 shares, the days-to-cover ratio is currently 9.2 days. Currently, 18.4% of the shares of the stock are short sold.
View Aerie Pharmaceuticals' Short Interest
.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Puma Biotechnology (PBYI), Wells Fargo & Co (WFC), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD) and Incyte (INCY).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
  • Mr. Thomas A. Mitro, Pres & COO (Age 61)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
  • Ms. Jessica Crespo CPA, Director of Accounting

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.16%), William Blair Investment Management LLC (2.95%), Bank of New York Mellon Corp (2.76%), Candriam Luxembourg S.C.A. (1.27%), Rhenman & Partners Asset Management AB (1.27%) and Frontier Capital Management Co. LLC (1.09%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which institutional investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, SG Americas Securities LLC, FMR LLC, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, and CWM LLC.
View insider buying and selling activity for Aerie Pharmaceuticals
.

Which institutional investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Goldman Sachs Group Inc., Granite Investment Partners LLC, Barclays PLC, Frontier Capital Management Co. LLC, Jefferies Group LLC, AlphaCrest Capital Management LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $12.70.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $590.73 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.